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We utilized a mouse model of acute promyelocytic leukemia (APL) to investigate how aberrant activation of
cytokine signaling pathways interacts with chimeric transcription factors to generate acute myeloid leukemia.
Expression in mice of the APL-associated fusion, PML-RARA, initially has only modest effects on myelopoiesis.
Whereas treatment of control animals with interleukin-3 (IL-3) resulted in expanded myelopoiesis without a
block in differentiation, PML-RARA abrogated differentiation that normally characterizes the response to IL-3.
Retroviral transduction of bone marrow with an IL-3-expressing retrovirus revealed that IL-3 and promyelo-
cytic leukemia-retinoic acid receptor alpha (PML-RAR) combined to generate a lethal leukemia-like syn-
drome in <21 days. We also observed that a constitutively activated mutant IL-3 receptor, cV449E, cooperated
with PML-RAR in leukemogenesis, whereas a different activated mutant, cI374N, did not. Analysis of
additional mutations introduced into cV449E showed that, although tyrosine phosphorylation of c is
necessary for cooperation, the Src homology 2 domain-containing transforming protein binding site is dis-
pensable. Our results indicate that chimeric transcription factors can block the differentiative effects of growth
factors. This combination can be potently leukemogenic, but the particular manner in which these types of
mutations interact determines the ability of such combinations to generate acute myeloid leukemia.
Numerous genetic abnormalities have been identified in hu-
man acute myeloid leukemia (AML) (3, 38). Alterations in
transcription factors have been observed in particular morpho-
logical subtypes of AML. In addition, alterations in molecules
that normally regulate cell behavior in response to external
cues (hereafter referred to as “signaling molecules”) are com-
mon in AML, but these types of mutations are less closely
associated with particular morphologies. In AML, chromo-
somal translocations commonly result in aberrant transcription
factors, whereas small intragenic mutations can lead to abnor-
mal transcription factors or mutant signaling molecules. An-
other type of alteration, chromosomal gain or loss, has been
seen in some cases of AML, but the critical genes affected by
these changes have not been definitively identified.
The number of genetic alterations required to cause human
AML is not known and may vary with the type of leukemia. De
novo leukemias with chromosomal translocations are believed
to be genetically simpler than leukemias arising after myelo-
dysplastic syndromes or cytotoxic chemotherapy, which are
often karyotypically complex. Of note, the proportion of AMLs
with simple translocations declines with age whereas, con-
versely, AMLs with complex karyotypes increase (49). Differ-
ences in karyotype, epidemiology, and response to therapy
indicate that AMLs are heterogeneous diseases. Therefore,
although there may be common elements and molecular path-
ways that result in conversion of normal hematopoietic cells to
AML, the types of genetic changes that in combination cause
leukemia are likely to be heterogeneous.
We sought to identify a simple combination of genetic
changes that is sufficient to cause leukemic transformation and
to examine the manner in which these changes exert their
cooperative effects. For this purpose, we utilized a transgenic
mouse model of acute promyelocytic leukemia (APL) in which
the MRP8 promoter is used to express a PML-RARA fusion
gene in myeloid cells.
The t(15;17)(q22;q12) results in the expression of a chimeric
promyelocytic leukemia-retinoic acid receptor alpha (PML-
RAR) fusion protein that is responsible for nearly 99% of all
human APLs (41, 50). There is evidence that, in fact, only a
small number of genetic changes are required to cause APL.
The t(15;17) is observed as the sole karyotypic change in 62%
of cases (37), and the incidence of APL is constant over the
human life span (56), suggesting one rate-limiting step. Al-
though it is conceivable that the t(15;17) is fully sufficient to
cause leukemia, there is evidence that additional mutations are
required. In 38% of cases, the t(15;17) is accompanied by
additional karyotypic changes (37), point mutations in genes
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encoding signaling molecules (such as FLT3) are common in
APL (28, 33, 51, 58, 59), and expression of the PML-RAR
fusion protein in mice initially has only a modest impact on
myelopoiesis (1, 15, 17).
With a median latency of 8.5 months, MRP8 PML-RARA
transgenic mice developed AML with features of human APL
(1). The transition from modest abnormalities of neutrophil
maturation to acute leukemia was accompanied by the appear-
ance of karyotypic abnormalities. Thus, this mouse model can
serve to identify genetic changes that cooperate with PML-
RAR to cause acute leukemia.
We have previously reported that BCL-2 decreased the la-
tency and increased the penetrance of leukemia in mice that
express PML-RARA. However, the BCL-2–PML-RAR com-
bination was not sufficient for the leukemic phenotype: there
was still a latency of 3 months, and recurring chromosomal
abnormalities and complex karyotypes were a constant feature
of the doubly transgenic leukemias (29, 37). In considering
events able to complete leukemic transformation, we noted
that preleukemic PML-RARA/BCL2 doubly transgenic mice
exhibited a marked impairment of neutrophil differentiation
but that, prior to the onset of acute leukemia, the immature
cells were not disseminated into nonhematopoietic tissues.
These results suggested that AML reflects not only impaired
differentiation but also relative autonomy from external cues.
We therefore hypothesized that providing continuous growth
factor stimulation to PML-RARA-expressing cells would be
sufficient to cause a rapidly fatal leukemia. We also hypothe-
sized that this model system could be used to elucidate the
cellular and molecular mechanisms through which such coop-
eration between cytokine signaling and chimeric transcription
factors occurs.
Our results show that PML-RAR blocks the neutrophil
differentiation that normally occurs when primary bone mar-
row cells are stimulated by growth factors and show that the
resulting inexorable expansion of immature cells is rapidly
fatal. Our results also indicate that the particular mix of signals
generated by activated growth factor receptors determines the
potential of such activation to contribute to acute leukemia.
These findings suggest a model of normal myelopoiesis in
which growth factor receptor activation generates a mix of
signals that balance increased proliferation and survival with
maintenance of maturation. Abrogation of the molecular
events that normally ensure differentiation in the face of a
growth stimulus is one pathway to AML.
MATERIALS AND METHODS
Mice. Mice were bred and maintained at the University of California at San
Francisco, and their care was in accordance with University of California at San
Francisco guidelines. MRP8 PML-RARA transgenic mice in the FVB/N back-
ground and control FVB/N mice were used for all experiments.
IL-3 injections. Transgenic and control mice were injected subcutaneously
with interleukin-3 (IL-3) at a dose of 200 ng (10 g/kg) three times a day for 4
days. Mice were euthanized, and tissues were harvested 8 h after the last injec-
tion.
Differentiation assays. Bone marrow from FVB/N and MRP8 PML-RARA
mice was harvested, depleted of red blood cells with Histopaque 1119 (Sigma) at
4°C according to the manufacturer’s instructions, and cultured in Myelocult 5300
(Stem Cell Technologies) with 10% X63Ag8–mIL-3 conditioned medium (25),
without or with all-trans-retinoic acid (ATRA; Sigma) at a concentration of 107
or 105 M.
Retroviral vectors. pMPZen-IL-3 is an IL-3-expressing retrovirus that does not
express any additional gene (2). pRufNeo retroviral constructs with cwt,
cV449E, and cI374N were described previously (22). We note that the amino
acid numbering of c is per the National Center for Biotechnology Information
reference sequence for CSF2RB (NP 000386). pRufNeo retroviral constructs
cV449E/Y593F, cV449E/Y766F, and cV449E/Y6xF (in which tyrosines 593,
628, 711, 766, 822, and 882 have all been mutated to phenylalanines) were
generated by site-directed mutagenesis of the cV449E construct and were
verified by sequencing.
Retroviral transductions. Donor mice were treated with 150 mg of 5-fluorou-
racil/kg, and marrow was harvested 5 days later. Marrow was prestimulated for
24 h in Dulbecco modified Eagle medium or Myelocult 5300 with 15% heat-
inactivated fetal bovine serum, 5% X63Ag8–mIL-3 conditioned medium, 100 U
of penicillin G/ml, 100 g of streptomycin/ml, 2 mM L-glutamine, 6 ng of mIL-
3/ml, 10 ng of mIL-6/ml, and 100 ng of stem cell factor/ml. BOSC23 cells (44)
were transfected with retroviral constructs. Marrow was transduced by spinocu-
lation with fresh retroviral supernatants (filtered through 0.45-m [pore-size]
filters) at 1,100  g in the presence of 2 g of Polybrene/ml for 1.5 h on two
consecutive days. Unsorted cells after transduction were introduced into lethally
irradiated (9 Gy, in two equal doses 3 to 6 h apart) or sublethally irradiated (4.5
Gy, as a single dose) mice.
Peripheral blood counts and bone marrow differential counts. Blood was
obtained from the retro-orbital sinus. White blood cell (WBC) count, hemoglo-
bin count, and platelet count were measured with the Hemavet 850 cell counter
(CDC Technologies). Blood smears and marrow smears were stained with
Wright’s Giemsa stain. Peripheral blood differential WBC counts (total of 200
cells each) and bone marrow differential counts (total of 400 cells each) were
determined as described previously (32). Some of the data included in Fig. 1 and
4 for control, PML-RARA preleukemic, and PML-RARA leukemic mice were
previously published (29, 30).
Histopathology. Tissues were initially fixed in either Bouin’s fixative or a
buffered formalin solution. Sternums fixed in formalin were decalcified for 2 to
3 h prior to embedding (formic acid 11%, formaldehyde 8%). Paraffin embedded
sections were stained with hematoxylin and eosin (H&E).
Immunophenotyping. After depletion of red blood cells, 300,000 bone marrow
and spleen cells were resuspended in 100 to 200 l of fluorescence-activated
cell-sorting buffer (buffered saline with 2% heat-inactivated fetal bovine serum
and 2.5% cell dissociation buffer [Gibco-BRL]). Cells were incubated with un-
labeled anti-CD16/CD32 antibodies (Fc block) for 15 min prior to the addition
of conjugated antibodies. The antibodies used included fluorescein isothiocya-
nate-conjugated antibodies to Ly-6G(Gr-1), CD59, CD86, CD34, CD45R(B220),
CD90.1(Thy1.1), CD41, and CD71; phycoerythrin (PE)-conjugated antibodies to
CD11b(Mac-1), CD31, CD117(c-kit), Ly-71(F4/80), CD19, CD3, CD61, and
Ly-76(Ter119); Tricolor-conjugated antibodies to CD45; and biotin-conjugated
antibody to hc, followed by treatment with PE-conjugated streptavidin. Anti-
bodies were incubated with the cells for 15 to 30 min in the dark on ice. Stained
cells were washed and analyzed on a FACScan or FACSCalibur apparatus
(Becton Dickinson), and at least 10,000 events were collected for each sample.
Fluorescence-activated cell sorting data were analyzed with CellQuest (Becton
Dickinson).
Transplantation of leukemias. Spleen cells of animals with leukemia were
washed and resuspended in buffered saline. A total of 106 cells were injected into
sublethally irradiated recipients by intravenous injection through the lateral tail
vein.
Additional studies. Treatment with ATRA by implanting 5-mg 21-day release
pellets was performed as described previously (1). A total of 106 cells from
spleens of ill mice were transplanted into sublethally irradiated recipients by
intravenous injection through the lateral tail vein. Cytogenetic and spectral
karyotyping analysis of spleen cells was performed as described previously (37).
For Southern blotting of PML-RAR/cV449E leukemias, the enzymes utilized
were KpnI (to assess presence of provirus) or BamHI (to assess the number of
integration sites) and the probe was the 1.1-kb neo cassette derived from pRuf-
Neo by digestion with BglII and ClaI.
Statistical analysis. Statistical analyses were performed with Excel 2000 by
using the Student t test or, for comparisons of survival curves, with GraphPad
Prism 3.0 by using the log-rank test.
RESULTS
PML-RAR has a modest impact on myelopoiesis in vivo.
Although PML-RAR has been observed to inhibit the differ-
entiation of cell lines and of primary cells in vitro (12–14, 48,
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54), we had observed that the expression of an MRP8 PML-
RARA transgene in mice had only a modest effect on hemato-
poiesis. Careful analysis of myelopoiesis in these mice revealed
subtle abnormalities (1, 29) (Fig. 1). Although peripheral
blood counts are indistinguishable from control animals, in the
bone marrow there is an increase in immature myeloid cells
(Fig. 1A). Immunophenotypic analysis revealed that, in addi-
tion to the decrease in Ly-6G(Gr-1) expression we previously
observed, the bone marrow of MRP8 PML-RARA transgenic
mice showed a modest increase in CD31 compared to controls
(Fig. 1B). This immunophenotypic profile reflects an increase
in immature cells because Ly-6G(Gr-1) expression increases
when neutrophilic cells mature and CD31 expression decreases
with myeloid maturation. Cytologic and histopathologic exam-
FIG. 1. PML-RAR has a modest effect on bone marrow myelo-
poiesis. (A) Bone marrow differential cell counts are shown. Control or
healthy preleukemic PML-RARA bone marrows were stained with
Wright’s Giemsa. Percentages of nucleated cells were derived from 400
cell differential counts. Imm/Bl, immature forms/blasts; Inter, interme-
diate forms (including neutrophilic and monocytic cells); Neu, mature
forms, neutrophilic; Lym, lymphocytes; Eos, eosinophilic cells; Mon,
mature monocytes. Bars: controls (), n  16; preleukemic PML-
RARA (), n  4. ❋, preleukemic PML-RARA marrow shows, com-
pared to control bone marrow, a modest increase in the number of
immature forms/blasts (P 0.01). The graphs depict arithmetic means
	 the standard deviation. (B) Flow cytometric immunophenotyping of
controls or healthy preleukemic PML-RARA transgenic bone marrows.
Histograms reflect gate  R1. Compared to the control bone marrow,
preleukemic PML-RARA transgenic bone marrow shows a decrease in
Ly-6G(Gr-1) and an increase in CD31 expression. (C) Cytology and
histopathology of control or preleukemic PML-RARA transgenic mice.
Subpanels: a, b, c, and d, control FVB/N; e, f, g, and h, preleukemic
PML-RARA; a and e, bone marrow smears stained with Wright’s Gi-
emsa (magnification, 400); b to d and f to h, H&E-stained histopa-
thology sections of bone marrow (magnification, 400) (b and f),
spleen (magnification, 100; insets, magnification, 400) (c and g),
and liver (magnification, 100) (d and h).
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ination revealed only subtle changes in the bone marrow; the
splenic and hepatic histopathology were not evidently different
from those of control animals (Fig. 1C).
PML-RAR blocks the differentiation that normally accom-
panies cytokine receptor activation. We initially selected IL-3
to test the hypothesis that growth factor stimulation would
cooperate with PML-RAR to cause leukemia. There were a
number of reasons for this choice. First, IL-3 expression had
been observed in 3 of 16 APLs studied (9). Second, the finding
that IL-3 cooperated with Hoxb8 to rapidly induce leukemia in
mice provided a precedent for our work (46). Third, because
the granulocyte-macrophage colony-stimulating factor (GM-
CSF)/IL-3/IL-5 receptors have been extensively studied, this
system is amenable to delineating critical downstream signals
(5, 7, 16).
We injected control and PML-RARA transgenic mice with
IL-3 for 4 days and assessed the effects of the cytokine. As has
been observed previously, short-term treatment with IL-3 had
little effect on the peripheral blood (42). In the bone marrow,
however, the increase in myelopoiesis and the shift toward
less-mature cells normally caused by IL-3 were enhanced by
the presence of PML-RAR (Fig. 2A). In PML-RARA trans-
genic mice, IL-3 caused more than 30% of the bone marrow
cells to accumulate at the immature form/blast stage of differ-
entiation. In addition, there was a trend toward decreased red
blood cell precursors. An increased number of blasts and a loss
of normal hematopoiesis are features of AML. These findings
indicated that, although PML-RAR had minimal effects on
differentiation under steady-state conditions in vivo, this chi-
meric fusion protein markedly interfered with differentiation
when a cytokine stimulus was present.
The ability of PML-RAR to block IL-3 induced differen-
tiation was corroborated by in vitro culture of control and
transgenic bone marrow cells (Fig. 2B). Short-term culture of
PML-RARA transgenic bone marrow in the presence of IL-3
was characterized by a marked deficit in mature neutrophils,
an abnormality that was substantially abrogated by the addition
of ATRA.
The combination of PML-RAR and IL-3 rapidly causes a
leukemia-like syndrome. In order to further examine the ef-
fects of combining PML-RAR with cytokine activation, we
utilized retroviral transduction of mouse bone marrow. We
harvested bone marrow from 5-fluorouracil-treated control
and PML-RARA transgenic mice. The bone marrow cells were
transduced with an IL-3-expressing retrovirus, and 300,000 to
FIG. 2. PML-RAR blocks differentiation that accompanies IL-3
receptor activation. (A) Bone marrow differential cell counts are
shown. Control or healthy preleukemic PML-RARA transgenic mice
were injected with IL-3 for 4 days. Bars: littermate controls (), n 
4; PML-RARA (), n  4. ❋, IL-3-injected PML-RARA transgenic
animals had, compared to IL-3-injected controls, significantly more
immature forms/blasts (P  0.003) and significantly fewer lymphocytes
(P  0.02). Trends toward fewer mature neutrophilic cells and ery-
throid cells were also evident. (B) Differential cell counts of in vitro
assays. Control or preleukemic PML-RARA transgenic bone marrows
were harvested, depleted of erythroid cells, and cultured in IL-3 with
or without ATRA for 24 h. Bars: littermate controls (), n  3;
PML-RARA (), n  4. Abbreviations are as described in Fig. 1A with
the following additions. In these in vitro assays, intermediate-stage
cells that were clearly neutrophilic (Inter/Neu) were enumerated sep-
arately from those that appeared monocytic (Inter/Mo); mature mono-
cytes and macrophages were enumerated together (Mo/Mac). (I) Con-
trol or PML-RARA transgenic bone marrow in IL-3 after 24 h; (II)
control or PML-RARA transgenic bone marrow in IL-3 plus ATRA at
107 M; (III) control or PML-RARA transgenic bone marrow in IL-3
plus ATRA at 105 M. ❋, for PML-RARA cells, immature forms/blasts
were markedly increased in IL-3 in culture after 24 h (compared to
FVB/N, P
 0.0001), and mature neutrophils were markedly decreased
(P  0.03). In the presence of ATRA, PML-RARA marrow yielded
significantly fewer immature forms/blasts and significantly more inter-
mediate and mature neutrophilic cells (compared to PML-RARA with-
out ATRA, P  0.01 at 107 M and 105 M ATRA). Of note, at 105
M ATRA, the numbers of immature forms/blasts and mature neutro-
philic cells were not significantly different between the FVB/N and
PML-RARA cultures.
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500,000 cells were injected into lethally irradiated nontrans-
genic histocompatible recipients. Recipients of PML-RARA
bone marrow transduced with IL-3 became ill with a lethal
myeloid disease within 14 to 16 days, whereas mice receiving
IL-3 transduced normal marrow became ill within 39 days to 11
weeks (Fig. 3).
If cytokine stimulation is sufficient to induce disease, then
injection of even relatively small numbers of transduced cells
into sublethally irradiated mice should also be rapidly fatal. We
therefore injected 50,000 cells after transduction into suble-
thally irradiated recipients. Again, the combination of PML-
RAR and IL-3 caused lethal myeloid disease rapidly, whereas
IL-3 alone caused illness more slowly and not all mice became
sick (Fig. 3).
We compared the character of the disease that arose in
recipients of control bone marrow transduced with IL-3 (con-
trol/IL-3-transduced mice) with that seen in recipients of PML-
RARA transgenic bone marrow transduced with IL-3. The pe-
ripheral blood of control/IL-3-transduced mice showed a
marked elevation in WBC counts, normal platelet numbers,
and moderate anemia in some animals (Fig. 4A). Numerous
mature neutrophilic forms were present, accompanied by a
substantial number of intermediate forms, but few immature
forms/blasts (Fig. 4B). Monocytosis and eosinophilia were also
evident. The bone marrow of these mice showed a marked
increase in myeloid cells in which a normal pattern of differ-
entiation was maintained (mature  intermediate  imma-
ture) (Fig. 4C). These results are similar to those previously
described (2, 57). Although the peripheral blood of PML-
RAR/IL-3 mice also showed increased WBC counts, moder-
ate anemia and marked thrombocytopenia were present (Fig.
4A). The leukocytosis was different from that seen in the con-
trol/IL-3 animals: differentiation was impaired with a shift to-
ward less-mature forms (Fig. 4B). In the bone marrow, the
combination of PML-RAR and IL-3 was characterized by
expansion of myeloid cells with numerous immature forms/
blasts but few mature neutrophils (Fig. 4C). Flow immunophe-
notyping (Fig. 4D) corroborated our morphological analysis:
compared to control/IL-3-transduced bone marrow, the my-
eloid cells of PML-RAR/IL-3-transduced bone marrow ex-
pressed increased markers of immaturity [CD34,
CD90.1(Thy1), CD31] and metabolic activity (CD71, the trans-
ferrin receptor), as well as somewhat higher levels of
CD11b(Mac-1) and Ly-71(F4/80), a marker expressed on ma-
ture monocytes and eosinophils that can also be expressed at
low levels on immature myeloid cells. Interestingly, the level of
Ly-6G(Gr-1) expression, which is lower than that of controls
for preleukemic PML-RARA transgenic mice, was induced to
normal levels by IL-3.
The ability of PML-RAR to block differentiation that nor-
mally accompanies IL-3 stimulus was also evident in smears
and sections of bone marrow and in the spleen and liver (Fig.
4E). Of note, the livers of both control/IL-3 and PML-RAR/
IL-3 mice were heavily infiltrated with myeloid cells. Whereas
spleens of control/IL-3 mice showed red pulp expansion with a
mix of myeloid cells, erythroid cells, and megakaryocytes, the
red pulp of PML-RAR/IL-3 mice was expanded predomi-
nantly with immature myeloid cells. The blood counts, marrow
morphology, histopathology, and rapid clinical course of dis-
ease observed in PML-RAR/IL-3 recipients are characteristic
of AML in mice.
To assess the response of the PML-RAR/IL-3 disease to
ATRA, sublethally irradiated recipients of PML-RAR/IL-3
bone marrow were treated with ATRA 10 days after injection.
The median survival of ATRA-treated mice was 45% longer
than the survival of untreated or placebo-treated mice (un-
treated/placebo treated, n  20, 16 to 19 days; ATRA treated,
n  4, 25 to 26 days; P  0.001).
Karyotypic analysis of six PML-RAR/IL-3 diseased recip-
ients was performed (Table 1). Five cases lacked clonal abnor-
malities, whereas in one case, 2 of 11 metaphase cells exhibited
a Robertsonian translocation (sample 740), which would not
be expected to result in altered gene expression. These results
contrast with the high frequency of clonal cytogenetic changes
and the distinct pattern of recurring numerical abnormalities
that we observed in PML-RAR (91%) and PML-RAR/
BCL-2 (100%) leukemias (29, 37). These cytogenetic findings
indicate that the combination of PML-RAR and IL-3 may be
fully sufficient to generate the leukemia-like syndrome ob-
served.
An activated IL-3 receptor cooperates with PML-RAR to
induce a transplantable AML with features of APL. To further
FIG. 3. IL-3 transduction of PML-RARA transgenic bone marrow
yields a rapidly fatal disease. Survival curves are shown. Control or
MRP8 PML-RARA transgenic bone marrow was transduced with a
retrovirus that expressed IL-3. Lethally irradiated recipients received
3  105 to 5  105 cells. Sublethally irradiated mice received 5  104
cells. The presence of PML-RARA was associated with more rapidly
progressing disease than that observed in the controls. Significance
values (PML-RAR/IL-3 versus control/IL-3): P  0.003 for lethally
irradiated recipients and P 
 0.0001 for sublethally irradiated recipi-
ents. Lethally irradiated recipients: PML-RAR/IL-3, n  4; control/
IL-3, n  6. Sublethally irradiated recipients: PML-RAR/IL-3, n 
19; control/IL-3, n  15.
TABLE 1. Karyotypic analysis of PML-RAR/IL-3 mice
Sample no. Karyotypea
730............................40,XX[13]/NCA:40,XX,t(2;4)(F3;D1)[1]
739............................40,XX[9]/NCA:39,X,ins(13;X)(B;A2D),18[1]
740............................39,XX,der(8;17)(A1;A1)[2]/40,XX[9]*
741............................40,XX[8]/NCA:41,XX,7[1]/40,XX9,15[1]
742............................40,XX[10]
743............................40,XX[10]
a NCA, nonclonal abnormality; *, Robertsonian translocation (centric fusion)
noted in two cells.
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investigate the ability of cytokine stimulation to cooperate with
PML-RAR in leukemogenesis, as well as to establish a system
in which to analyze the mechanisms underlying this coopera-
tion, we utilized activated versions of the IL-3 receptor. The
IL-3 receptor is part of a family of cytokine receptors that
includes GM-CSF and IL-5. In humans, these three receptors
have distinct alpha chains but share a beta chain (c). In mice
there is an alternative  chain (IL-3) that combines with the
IL-3 receptor alpha chain to generate a second class of IL-3
receptor. We have utilized activated versions of human c that
have been previously demonstrated to confer cytokine inde-
pendence to mouse cells and have been used to enhance our
understanding of GM-CSF/IL-3/IL-5 signal transduction (Fig.
5) (21, 22, 39). Although activating mutations in c have not
FIG. 4. PML-RAR and IL-3 disease has features of AML. (A to C)
Blood and bone marrow analyses of diseased recipients of IL-3-trans-
duced control and PML-RARA transgenic bone marrow are shown. The
results are compared to normal FVB/N mice and leukemias that arose
spontaneously in MRP8 PML-RARA transgenic animals. (A) Peripheral
blood: WBC, 10,000/l; hemoglobin (HGB), grams/deciliter, platelet
count (PLT), 100,000/l.❋, control/IL-3 mice exhibited leukocytosis (P
0.01), displayed a trend toward anemia, and were not thrombocytopenic.
PML-RAR/IL-3 mice exhibited leukocytosis, anemia, and thrombocyto-
penia (P  0.004). Bars: control FVB/N (), n  14; leukemias from
PML-RARA mice (o), n 10; control/IL-3 ( ), n 6; PML-RAR/IL-3
(), n  10. (B) Peripheral blood: percentage of nucleated WBCs. ❋,
compared to control/IL-3 mice, PML-RAR/IL-3 mice had increased
immature forms/blasts (P  0.01), increased intermediate forms (P 
0.01), and decreased mature neutrophils (P  0.0001). Bars: control
FVB/N (), n 8; leukemias from PML-RARA mice (o), n 6; control/
IL-3 ( ), n  5; PML-RAR/IL-3 (), n  5. (C) Bone marrow: per-
centage of nucleated cells. ❋, compared to control/IL-3 mice, PML-
RAR/IL-3 mice had increased immature forms/blasts (P  0.01) and
decreased mature neutrophils (P 0.0003). Not shown are mast cells that
comprised 4% of cells in control/IL-3 marrow, 0.7% of cells in PML-
RAR/IL-3 marrow, and 
0.25% of cells in control and PML-RAR
leukemic marrows. Bars: control FVB/N (), n  16; leukemias from
PML-RARA mice (o), n  6; control/IL-3 ( ), n  5; PML-RAR/IL-3
(), n  5. (D) Flow cytometric immunophenotyping of control/IL-3 or
PML-RAR/IL-3 bone marrow. Histograms reflect gate  R2. Com-
pared to control/IL-3 bone marrow, PML-RAR/IL-3 shows an increase
in CD71, CD11b, CD34, CD90.1, CD31, and F4/80 expression. (E) Cy-
tology and histopathology of diseased recipients of IL-3 transduced control or
PML-RARA transgenic bone morrow. Subpanels: a to d, control/IL-3; e, f, g,
and h, PML-RAR/IL-3; a and e, bone marrow smears stained with Wright’s
Giemsa (magnification, 400); b to d and f to h, histopathology sections
stained with H&E; b and f, bone marrow (magnification, 400); c and
g, spleen (magnification, 400); d and h, liver (magnification, 100).
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been reported in human AML (11), we used this system to
investigate mechanisms of cooperative leukemogenesis.
We transduced control and PML-RARA transgenic bone
marrow with wild-type (cwt) and activated (cV449E; cV433E
if the signal sequence is excluded) receptors and reconstituted
lethally irradiated recipients. Mice were monitored for the de-
velopment of disease, and ill animals were analyzed. cV449E
cooperated with PML-RAR to induce leukemias (Fig. 6A).
These leukemias were characterized by leukocytosis, anemia,
and thrombocytopenia. Immature forms/blasts were evident in
the peripheral blood, and bone marrows were marked by the
accumulation of numerous immature myeloid cells (Fig. 6B).
Flow immunophenotyping corroborated the observed mor-
phology since the leukemias were composed of immature my-
eloid cells that expressed both Ly-6G(Gr-1) and CD11b(Mac-
1), as well as CD117(c-kit) and CD34. In addition, there was
strong expression of CD61, CD59, and CD31. The cells lacked
the lymphocyte markers CD3, CD19, and CD45R, as well as
the erythroid marker Ly-76(Ter119) (Fig. 6C). Cytology of
bone marrow and histopathology of tissues showed the illness
to be a disseminated disease of immature myeloid cells (Fig.
6D). In contrast to our observation that we could not consis-
tently transmit PML-RAR/IL-3 disease to secondary recipi-
ents, the PML-RAR/cV449E leukemias were readily trans-
plantable (Fig. 6E).
PML-RAR/cV449E leukemias were responsive to reti-
noic acid. Sublethally irradiated recipients of 106 cells from a
PML-RAR/cV449E animal were treated with placebo or
5-mg ATRA pellets on day 14 after transplantation of the
leukemia. The median survival of ATRA-treated mice was
33% longer than the median survival of placebo-treated mice
(placebo treated, n  6, 19 to 22 days; ATRA treated, n  6,
27 to 32 days; P  0.001). Interestingly, this effect on survival
was similar to the 45% prolongation observed in PML-RAR/
IL-3 mice treated with ATRA (see above) but appeared to be
less than the twofold median prolongation of survival caused
by ATRA when PML-RAR leukemias without activation of
the IL-3 receptor were treated (29, 36).
We also examined the karyotypes of the PML-RAR/
cV449E leukemias. As shown in Table 2, seven of nine (78%)
leukemias had clonal abnormalities, which included the gain of
chromosome 15 in two cases and gain of chromosome 8 in
seven cases. Four cases showed loss of an X chromosome.
FIG. 5. Diagram of hc retroviral constructs that gives a schematic
representation of activating c constructs. The extracellular domains
are numbered 1 to 4 from the amino terminus. Six intracellular ty-
rosines residues are indicated. Amino acid I374 is located in cytokine
receptor domain 4 (CRD4) of the extracellular region; activated re-
ceptor cI374N has an isoleucine at amino acid 374 mutated to aspar-
agine. Amino acid V449 is located in the transmembrane region; ac-
tivated receptor cV449E has a valine at amino acid 449 mutated to
glutamic acid. cV449E/Y593F, in addition to V449E, also has a ty-
rosine mutated to a phenylalanine at amino acid 593. Similarly,
cV449E/Y766F has a V449E mutation and a tyrosine at position 766
mutated to a phenylalanine. cV449E/Y6xF has six cytoplasmic ty-
rosine residues mutated to phenylalanine in addition to the V449E
transmembrane mutation.
FIG. 4—Continued.
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In light of these clonal karyotypic abnormalities, we exam-
ined whether splenic DNA of PML-RAR/cV449E leuke-
mias also demonstrated a monoclonal (or oligoclonal) pattern
of retroviral insertion sites. Interestingly, Southern blot anal-
yses of four leukemias, including two leukemias for which we
had cytogenetic data (samples 108 and 363), demonstrated that
proviral DNA was present in the leukemias (Fig. 7A) and that
there was more than one site of integration in each sample,
with various band intensities indicative of multiple clones (Fig.
7B). A number of explanations for the contrasting clonality
FIG. 6. PML-RAR cooperates with activated hc receptor to induce AML. (A) Survival curves. Control or MRP8 PML-RARA transgenic bone
marrow was transduced with pRufNeo-hcV449E or pRufNeo-hc(wild-type) retroviruses. (I) Lethally irradiated recipients received 5 10
5 cells.
Curves: control/cV449E, n  6; control/c (wild type), n  6; PML-RAR/cV449E, n  8; PML-RAR/c (wild type), n  4. (II) Sublethally
irradiated mice received 5 104 cells. Curves: control/cV449E, n 9; control/c (wild type), n 5; PML-RAR/cV449E, n 9; PML-RAR/c
(wild type), n 5. Lethally irradiated PML-RAR/cV449E recipients were sick within 60 days with a median of 49 days and sublethally irradiated
recipients PML-RAR/cV449E mice were sick within 80 days with a median of 60 days. Compared to PML-RAR/c (wild type) mice (some of
which developed leukemia after 160 days), the decreased latency of leukemia in PML-RAR/cV449E mice was statistically significant (P  0.02
for lethally irradiated recipients and P 
 0.01 for sublethally irradiated recipients). (B) Blood and bone marrow analyses of diseased recipients of
cV449E transduced PML-RARA transgenic bone marrow. Bars (peripheral blood counts [top graph]): PML-RAR/cV449E, n  12; WBC,
10,000/l; hemoglobin (HGB), grams/deciliter; platelet count (PLT), 100,000/l. PML-RAR/cV449E leukemic mice showed high blood cell
counts and are anemic and thrombocytopenic. Peripheral blood differential cell counts (n  5) are shown in the middle panel as a percentage of
nucleated WBCs. PML-RAR/cV449E mice showed increased immature forms/blasts, increased intermediate forms, and decreased mature
neutrophilic forms compared to control mice (Fig. 4B). Bone marrow differential cell counts (n 5) are shown in the bottom panel as a percentage
of nucleated cells. Counts are markedly different from those of control mice. (C) Flow cytometric immunophenotyping of PML-RAR/cV449E
bone marrow. Bone marrow samples of mice transduced with PMLRAR/cV449E were stained with FITC-, PE- and Tricolor-conjugated
antibodies. Histograms reflect gate  R1 and R2. ❋, antibody recognizes CD90.2. Because FVB/N mice express CD90.1, the few cells stained
represent cross-reactivity or nonspecific staining. (D) Cytology and histopathology of leukemic recipients of cV449E transduced PML-RARA
transgenic bone morrow. Subpanels: a, bone marrow smear stained with Wright’s Giemsa (magnification, 400); b to d, histopathology sections
stained with H&E; b, bone marrow (magnification,400); c, liver (magnification,100); d, spleen (magnification,100) and higher-magnification
insets of the spleen (magnification, 400). (E) Leukemias were readily transplantable. A survival curve of sublethally irradiated recipients of
PML-RAR/cV449E leukemias (n  9) is shown.
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results obtained by karyotypic and Southern blot analyses are
considered below (see Discussion).
Tyrosine phosphorylation of activated beta common is es-
sential for cooperation with PML-RAR. Mutations in the
juxtamembrane region (extracellular) and transmembrane re-
gion of c can activate the receptor and confer cytokine inde-
pendence onto factor-dependent cell lines and primary hema-
topoietic cells (22, 39). Whereas cV449E exemplifies the
transmembrane mutations, cI374N (cI358N, signal sequence
excluded) exemplifies the juxtamembrane class of mutations.
Because these classes of mutations differ in their biological and
biochemical effects (21, 40), we compared the combination of
cI374N and PML-RAR with what we had observed with
PML-RAR plus cV449E. In contrast to the latter, cI374N
did not cooperate with PML-RAR to induce leukemia (Fig.
8).
Previous studies had demonstrated that cV449E exhibited
ligand-independent phosphorylation of the intracellular ty-
rosine residues of c, whereas cI374N did not exhibit detect-
able ligand-independent tyrosine phosphorylation (21). We
therefore hypothesized that signals derived from the phosphor-
ylated tyrosines of c were responsible for the ability of this
activated cytokine receptor to cooperate with PML-RAR
in leukemogenesis. We tested this hypothesis by utilizing
cV449E/Y6xF in which tyrosines 593, 628, 711, 766, 822,
and 882 have all been mutated to phenylalanines. Although
cV449E/Y6xF retains two tyrosines located near the trans-
membrane-intracellular junction, cV449E/Y6xF did not co-
operate to induce acute leukemia (Fig. 8).
Particular tyrosines of c have been implicated in specific
biochemical functions. Y593F (Y577F, signal sequence ex-
cluded) is the binding site for Src homology 2 domain-contain-
ing transforming protein (SHC) and may also contribute to
phosphorylation of protein tyrosine phosphatase, non-receptor
type 11 (SHP-2) (10, 20, 43). Y766F (Y750F, signal sequence
excluded) can contribute to STAT activation (although it is not
necessary for such activation) and may enhance tyrosine phos-
phorylation on c (10, 19, 55). Interestingly, both cV449E/
Y593F and cV449E/Y766F were able to cooperate with PML-
RAR to induce leukemia (Fig. 8), indicating that these
individual tyrosines were not essential for cooperative leuke-
mogenesis. These leukemias were phenotypically similar to
those arising in PML-RAR/cV449E recipients (data not
shown). There was a trend toward prolonged survival in the
presence of these point mutations (P
 0.05). Nevertheless, we
FIG. 6—Continued.
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cannot definitively conclude that these point mutations influ-
enced latency because (i) there are small numbers of mice per
group, (ii) at least one animal in each group became ill in 
50
days, and (iii) it is possible that differences in viral titers influ-
enced survival.
DISCUSSION
We have utilized MRP8 PML-RARA mice to investigate how
genetic changes cooperate in myeloid leukemogenesis. We ob-
served that, whereas PML-RAR had only modest effects
on myelopoiesis and cytokine stimulation alone resulted in
expanded myelopoiesis with retained differentiation, PML-
RAR blocked the differentiation that normally accompanies
growth factor stimulus. IL-3 combined with PML-RAR to
rapidly generate a lethal disease with pathological features of
AML. An activated c chain similarly cooperated with PML-
RAR to generate a transplantable AML. Analysis of various
activated c chains showed that (i) the ability to confer cyto-
kine independence, per se, is not sufficient for cooperative
leukemogenesis; (ii) signals induced by phosphotyrosines are
critical for transformation in this system; and (iii) a tyrosine
residue critical for SHC activation is not required for cooper-
ation with PML-RAR.
The combination of PML-RAR and IL-3 resulted in a
disease with features of murine AML: accumulation of numer-
ous immature forms/blasts, anemia and thrombocytopenia, dis-
semination of immature cells outside of the bone marrow and
spleen, and rapid lethality. Injections of small numbers of cells
immediately after transduction into sublethally irradiated mice
was fatal in 
21 days. In addition, in contrast to previous
studies of leukemias in MRP8 PML-RARA transgenic mice,
clonal cytogenetic changes were observed in only one of six
leukemias studied, and in the one case, only a minority of cells
showed a nonpathogenic chromosomal abnormality. These re-
sults strongly suggest that PML-RAR plus IL-3 are sufficient
to cause a leukemia-like syndrome.
We wanted to demonstrate that cytokine receptor activation
would cooperate with PML-RAR in a cell autonomous man-
ner in order to develop a system in which we could delineate
the mechanisms contributing to leukemic transformation.
For this reason, we made use of an activated c chain of the
GM-CSF/IL-3/IL-5 receptor family. Like IL-3, cV449E coop-
erated with PML-RAR and in fact gave rise to a transplant-
able AML with features of APL.
Differences between our results with IL-3 and cV449E ret-
roviruses are likely due in part to cell nonautonomous effects
of the IL-3 retrovirus. Mice reconstituted with bone marrow
transduced with the IL-3 retrovirus have markedly elevated
IL-3 levels in serum (46). IL-3 is therefore able to influence not
FIG. 7. PML-RAR/cV449E leukemias have multiple proviral in-
sertion sites. Genomic DNAs derived from spleen samples of PML-
RAR/cV449E leukemic mice were used to assess retroviral integra-
tion. Filters were probed with a 1.1-kb Neo probe derived from
pRufNeo. The sizes of molecular weight markers are shown in kilo-
bases. (A and B) Genomic DNAs were digested with KpnI (which cuts
in each viral long terminal repeat) to assess the presence of provirus
(A) or digested with BamHI to assess the number of integration sites
(B). BamHI cleaves once within the retroviral sequence; therefore,
each band represents a site of retroviral integration.
FIG. 8. Tyrosine phosphorylation of hc is essential for coopera-
tion with PML-RAR. Compared to PML-RAR/cV449E leukemic
recipients, mice that received PML-RARA bone marrow transduced
with cI374N (n  17) and cV449E-Y6xF (n  8) did not become ill
in the first 200 days. Both cV449E/Y593F (n  7) and cV449E/
Y766F (n  3) mice developed leukemia. The phenotype of these
leukemias was similar to that observed in PML-RAR/cV449E mice
(data not shown).
TABLE 2. Karyotypic analysis of PML-RAR/c V449E leukemias
Sample no. Karyotypea
108.........................40,XY[14]/NCA:39,X,Y,14[1]
109.........................42,XY,8,15[10]
112.........................41,XY,8[2]/40,XY[8]
362.........................40,X,X,8[2]/NCA:41,XX,15[1]
363.........................40,X,X,15[7]/40,X,X,8[2]/40,XX[3]
365.........................40,XX[14]/NCA:41,XX,8[1]
366.........................40,X,X,8[2]/40,XX[10]
396.........................39,X,X[3]/40,idem,8[6]/NCA:40,idem,15[1]
398.........................41,XX,8[8]/NCA:41,idem,9,16[1]/40,XX[1]
a NCA, nonclonal abnormality.
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only the transduced cells but also nontransduced cells in the
transplanted marrow and in host cells as well. The shorter
latency of disease in PML-RAR/IL-3 mice compared to
PML-RAR/cV449E recipients is therefore probably due, at
least partially, to the impact of IL-3 on nontransduced cells.
Supporting this possibility is the fact that, whereas injection of
50,000 PML-RARA cells transduced with IL-3 was fatal to
sublethally irradiated recipients in 
20 days (Fig. 3), injection
of 1,000,000 cells from PML-RAR/cV449E leukemic mice
took 20 days to cause lethality (Fig. 6E, P 
 0.001) and the
latency of leukemia after injection of 50,000 cells from PML-
RAR/cV449E leukemic mice into sublethally irradiated re-
cipients was 67 days (data not shown). Cell nonautonomous
effects of IL-3 might also contribute to the lack of transplant-
ability of PML-RAR/IL-3 disease to secondary recipients. In
addition, the fact that five of six karyotypes of PML-RAR/
IL-3 disease were normal, whereas seven of nine PML-RAR/
cV449E leukemias were abnormal could similarly reflect the
ability of secreted IL-3 to expand both transduced and untrans-
duced PML-RAR-expressing cells.
Our findings that the PML-RAR/cV449E leukemias ex-
hibited clonal karyotypic abnormalities, whereas the patterns
of proviral insertion suggested oligo- or polyclonality, raise
interesting questions regarding the sufficiency of the combina-
tion of PML-RAR and cV449E to fully transform normal
blood cells into acute leukemia. One possibility is that PML-
RAR plus cV449E is sufficient for transformation, that this
is reflected in the multiple insertion sites present in the spleens
of leukemic mice, and that the clonal karyotypic abnormalities
reflect the rapid acquisition of cytogenetic changes, with clonal
selection, taking place within already-transformed cells. Alter-
natively, PML-RAR plus cV449E may induce a preleukemic
state characterized by expanded myelopoiesis that is not ini-
tially acute leukemia. The proviral insertion patterns could
reflect persistence of multiple preleukemic clones in the
spleens of leukemic mice. If this is the case, then additional
genetic changes, reflected as clonal karyotypic abnormalities,
are necessary and, in this system, inevitable. Inducible systems
represent a powerful approach for assessing sufficiency in ma-
lignant transformation (45). Studies of mice carrying a PML-
RARA transgene in combination with an inducible activated
cytokine receptor could clarify the number of steps required
for leukemogenesis.
An important finding from this work was that growth factor
independence does not necessarily permit cooperation with
PML-RAR in leukemogenesis, that is, differences among
events able to confer factor independence can influence the
potency of cooperation. We observed that although cI374N,
like cV449E, is able to confer growth factor independence
and activate mitogen-activated protein kinase, JAK2, and
STAT5 (21), cI374N did not readily cooperate with PML-
RAR to generate AML. What then underlies this difference
between these two versions of an activated receptor? At the
cellular level, cI374N and cV449E have different effects on
the murine factor-dependent FDB cell lines (40). Both confer
factor independence, but FDB cells that grow and survive due
to the presence of cI374N undergo differentiation, whereas
FDB cells dependent on cV449E remain undifferentiated.
Therefore, when these activated receptors are expressed in
vivo, the signals generated by cI374N might foster greater
maturation than those caused by cV449E. Of note, activated
FLT3, which like cV449E has been reported to favor contin-
ued proliferation while impairing maturation (60), does coop-
erate with PML-RAR to cause leukemia (27, 53). At the
molecular level, known qualitative differences between the
cI374N and cV449E mutants that might underlie their
different effects include the following: (i) cI374N results in
ligand-independent association with the  chain of mouse
GM-CSF receptor; (ii) cV449E but not cI374N results in
phosphorylation of the tyrosines in the intracytoplasmic region
of c; and (iii) such phosphorylation results in SHC activation
in cells that express cV449E but not cI374N (21, 23; T. Blake
and T. Gonda, unpublished observations). A lack of SHC ac-
tivation in PML-RARA cells transduced with cI374N was a
possible explanation for the lack of cooperative leukemogen-
esis we observed with cI374N, but the cV449E/Y593F con-
struct, which lacks the SHC binding site, still cooperated with
PML-RAR to cause leukemia. The fact that mutations of six
tyrosines of c in the cV449E/Y6xF construct blocked coop-
eration indicates that signals generated by phosphorylation of
these tyrosines are critical, and the fact that cV449E/Y766F
did cooperate highlights the redundancy of the signals gener-
ated by interactions with these tyrosines (10, 19, 43, 55). The
use of additional c mutations, as well as complementary ap-
proaches to assessing the importance of downstream effectors,
should permit our model system to be further utilized in iden-
tifying critical mediators through which activated cytokine re-
ceptors contribute to AML.
Given the subtle impact of PML-RAR on myelopoiesis in
vivo, what is the role of this protein in APL? The transcrip-
tional effects of PML-RAR, including the ability of PML-
RAR to repress transcription through recruitment of histone
deacetylases (41) and DNA methyltransferases (8), likely un-
derlies the ability of this protein to cause a subtle increase in
immature myeloid cells. In addition, by inhibiting PML’s ability
to induce apoptosis, PML-RAR may foster the acquisition of
additional pathogenic mutations in this expanded immature
cellular compartment (47). Finally, as we have demonstrated,
PML-RAR contributes to a profound block in differentiation
in the presence of additional genetic lesions. PML-RAR ex-
emplifies a principle that seems to apply to transcription factor
mutations that contribute to human AML: it has multiple ef-
fects that each individually contribute to transformation.
One type of cooperating event, activation of cytokine recep-
tors on its own fosters proliferation and survival and main-
tained differentiation. An appropriate balance in the cellular
response to growth factors permits expansion of the immature
or mitotic compartment while ensuring the generation of large
numbers of mature effector cells. Recent data suggest that
growth factor-induced activation of RARs may in fact be the
basis for the differentiation response. For example, both GM-
CSF and IL-3 enhance the activity of RARs (24, 52). Although
under steady-state conditions loss of RAR activity has, like the
expression of PML-RAR, mild effects on myelopoiesis (26,
35), it is plausible that PML-RAR blocks the increased RAR
activity induced by growth factor stimulation. This block would
thus abrogate a differentiation signal required to maintain neu-
trophil production in the presence of increased cytokine re-
ceptor activation.
It is notable that specific expression of a number of translo-
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cation proteins in myeloid cells, including PML-RAR, AML1-
ETO, and CBF-SMMHC, can have modest in vivo effects (1,
15, 17, 18, 31). It therefore appears that the genetic changes of
AML central to impaired differentiation are able to block
maturation only when accompanied by changes that promote
autonomous growth. This idea is supported by the observations
that activated FLT3 cooperates with PML-RAR (27, 53) and
that BCR-ABL cooperates with AML1-MDS1-EVI1 or
NUP98-HOXA9 (4, 6) to cause acute leukemia. By under-
standing the critical events that underlie cooperative effects,
we should be able to therapeutically tip the cells of human
AMLs back toward normal behavior, as has been done suc-
cessfully for APL. Our findings explore one pathway for leu-
kemic transformation, i.e., cooperation of abnormal transcrip-
tion factors with activated cytokine receptors, and provide a
system for identifying the particular signals that are critical for
this process. Other pathways for leukemic transformation al-
most certainly exist, including overexpression of complement-
ing transcription factors (e.g., Hoxa9 plus Meis1a [34]), as well
as unidentified events in the karyotypically complex leukemias
seen after myelodysplasia, cytotoxic chemotherapy, and in the
elderly. Further work is needed to reveal whether these differ-
ent types of AML share fundamental molecular abnormalities.
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AUTHOR’S CORRECTION
Cooperation of Cytokine Signaling with Chimeric Transcription
Factors in Leukemogenesis: PML-Retinoic Acid Receptor
Alpha Blocks Growth Factor-Mediated Differentiation
Vernon T. Phan, David B. Shultz, Bao-Tran H. Truong, Timothy J. Blake,
Anna L. Brown, Thomas J. Gonda, Michelle M. Le Beau,
and Scott C. Kogan
Department of Laboratory Medicine and Comprehensive Cancer Center, University of California at San Francisco,
San Francisco, California; Hanson Institute and Division of Human Immunology, Institute of Medical and
Veterinary Science, Adelaide, South Australia, Australia; and Section of Hematology/Oncology,
University of Chicago, Chicago, Illinois
Volume 23, no. 13, p. 4573–4585, 2003. We regret that the construct labeled cI374N in Fig. 5 and 8 and in the text has been
found to be cI374A, a construct that is not constitutively activated. Following the discovery of this unfortunate error, we have
transduced PML-RARA transgenic bone marrow with the correct cI374N construct. In contrast to what we reported, cI374N can,
like cV449E, cooperate with PML-RARA to induce leukemias with features of acute promyelocytic leukemia. Hence, although
we believe that the other results and conclusions of the work are correct (including the central point of the paper, the cooperation
of cytokine signaling with PML-RAR in blocking differentiation and inducing leukemia), the results that we presented and
discussed for cI374N (Discussion, paragraph 6) are incorrect. We apologize for any difficulties or confusion that this error may
have caused for our colleagues.
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